News

Hosted on MSN10d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
KDFW10d
Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial
This trial consisted of 751 people in the U.S. who were overweight or had obesity and roughly one other weight-related ...
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...